, /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent notice of allowance for opaganib[4] in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response, providing protection for opaganib's potential use with a range of approved and in-development immune checkpoint inhibitors (ICIs) across a growing range of indications through 2040. The patent will be issued by the Chinese National Intellectual Property Administration (CNIPA) (Chinese Patent Application No.
: 202080013805.3 issued ). "ICIs have become a cornerstone in cancer treatment, having been hailed as a major breakthrough by oncologists, with the global ICI market expected to exceed by 2028, including Merck's Keytruda (pembrolizumab) and BMS' Yervoy (ipilimumab)," .
"This exciting new patent is based on compelling data from a range of experiments showing significant improvements in outcomes in combination with selected ICIs. has been a world leader in embracing ICI-based therapy[5] and this is an important addition to the strong patent portfolio protecting opaganib." Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple potential diseases, including prostate .
